Proposed experiment from debate on Synaptic pruning by microglia in early AD

Proposed experiment from debate on Synaptic pruning by microglia in early AD

Background and Rationale

This study tests whether complement-mediated synaptic pruning can be therapeutically modulated using decoy molecules in Alzheimer's disease mouse models. The complement system, particularly C1q, has emerged as a key mediator of pathological synapse loss in AD through tagging synapses for microglial elimination. This falsification experiment uses C1q-sufficient versus C1q-deficient AD transgenic mice (5xFAD or APP/PS1) treated with synthetic C1q decoy molecules designed to compete with endogenous C1q for synaptic binding sites. The approach tests whether blocking complement-mediated synapse tagging can preserve synaptic density and cognitive function in AD models. The study incorporates comprehensive synaptic analysis using electron microscopy, immunohistochemistry for synaptic markers (PSD95, synaptophysin), and electrophysiological recordings to assess functional connectivity. Additionally, systemic immune function monitoring ensures that therapeutic intervention doesn't compromise peripheral immunity.

...

Proposed experiment from debate on Synaptic pruning by microglia in early AD

Background and Rationale

This study tests whether complement-mediated synaptic pruning can be therapeutically modulated using decoy molecules in Alzheimer's disease mouse models. The complement system, particularly C1q, has emerged as a key mediator of pathological synapse loss in AD through tagging synapses for microglial elimination. This falsification experiment uses C1q-sufficient versus C1q-deficient AD transgenic mice (5xFAD or APP/PS1) treated with synthetic C1q decoy molecules designed to compete with endogenous C1q for synaptic binding sites. The approach tests whether blocking complement-mediated synapse tagging can preserve synaptic density and cognitive function in AD models. The study incorporates comprehensive synaptic analysis using electron microscopy, immunohistochemistry for synaptic markers (PSD95, synaptophysin), and electrophysiological recordings to assess functional connectivity. Additionally, systemic immune function monitoring ensures that therapeutic intervention doesn't compromise peripheral immunity. This research addresses a critical gap in understanding whether complement inhibition represents a viable therapeutic strategy for preserving synapses in AD, while testing the specificity and safety of targeting this pathway.

This experiment directly tests predictions arising from the following hypotheses:

• Complement C1q Mimetic Decoy Therapy
• SASP-Mediated Complement Cascade Amplification
• Complement C1q Subtype Switching
• TREM2-mediated microglial tau clearance enhancement
• TREM2 Conformational Stabilizers for Synaptic Discrimination

Experimental Protocol

Phase 1: Animal Preparation and Randomization (Weeks 1-2)
• Obtain 120 APP/PS1 transgenic mice (8-10 weeks old) and 60 C1q knockout (C1qa-/-) mice crossed with APP/PS1
• Randomize into 6 groups (n=30 each): APP/PS1+vehicle, APP/PS1+decoy, APP/PS1+scrambled decoy, C1qa-/-APP/PS1+vehicle, C1qa-/-APP/PS1+decoy, C1qa-/-APP/PS1+scrambled decoy
• Baseline cognitive testing using Morris water maze and novel object recognition
• Collect baseline blood samples for immune profiling

Phase 2: Decoy Molecule Treatment (Weeks 3-14)
• Administer C1q decoy molecules (10 mg/kg) or scrambled control via osmotic pumps replaced bi-weekly
• Weekly body weight monitoring and general health assessment
• Bi-weekly blood collection for C1q levels and immune markers

Phase 3: Systemic Immune Function Testing (Weeks 8-10)
• Bacterial clearance assay: Inject E. coli (10^6 CFU) i.p., measure bacterial load in blood/organs at 4, 8, 24h
• Autoantibody assessment: Weekly serum collection for anti-nuclear antibody (ANA) and anti-dsDNA ELISA
• Complete blood count and flow cytometry for immune cell populations

Phase 4: Cognitive and Neuropathological Assessment (Weeks 12-14)
• Morris water maze testing for spatial memory
• Novel object recognition for recognition memory
• Contextual fear conditioning for associative memory

Phase 5: Terminal Analysis (Week 15)
• Perfusion fixation and brain harvesting
• Immunohistochemistry for amyloid plaques (6E10), microglia (Iba1), synapses (PSD95, synaptophysin)
• Quantitative analysis of plaque burden, microglial activation, and synaptic density in hippocampus and cortex
• Western blot analysis for C1q, C3, and synaptic proteins

Expected Outcomes

C1q decoy treatment will reduce synaptic pruning by 40-60% compared to vehicle controls in APP/PS1 mice, measured by preserved PSD95+ puncta density (p<0.01)

Decoy-treated mice will show 25-35% improvement in Morris water maze performance compared to vehicle controls (escape latency reduction, p<0.05)

Systemic immune function will be compromised in decoy-treated mice: 50-70% reduced bacterial clearance efficiency and 2-3 fold increase in autoantibody titers (p<0.01)

Amyloid plaque burden will increase by 30-50% in decoy-treated APP/PS1 mice due to impaired microglial phagocytosis (p<0.01)

C1qa-/- mice will show no additional benefit from decoy treatment, confirming C1q-specific mechanism

Microglial activation markers (CD68, TREM2) will be reduced by 20-40% in decoy-treated groups, indicating suppressed phagocytic function

Success Criteria

• Significant preservation of synaptic markers (PSD95, synaptophysin) in decoy-treated vs control mice (effect size >0.8, p<0.01)
• Measurable cognitive improvement in at least 2 out of 3 behavioral tests with effect size >0.6 (p<0.05)
• Demonstration of systemic immune impairment: bacterial clearance reduced >40% or autoantibody levels increased >2-fold (p<0.01)
• Increased amyloid burden in decoy-treated mice by >25% compared to controls, confirming loss of beneficial C1q function (p<0.05)
• No differential response to decoy treatment in C1qa-/- mice compared to vehicle (p>0.05), validating target specificity
• Minimum 85% animal survival rate and successful decoy delivery confirmed by >70% reduction in detectable C1q activity in treated groups